- Improving surveillance
Two KalaCORE surveillance officers have been placed in Amhara and Tigray Regional Health Bureaus and work to strengthen surveillance and outbreak response capacity. Joint assessments are carried out of hotspot areas for VL in these regions in collaboration with VL focal persons within the RHBs. KalaCORE is providing advice on establishing VL diagnostic and treatment services to increase access for the patients. KalaCORE is supporting 5-10 years VL retrospective data collection to improve data.
- Training health workers
Three Clinical Mentoring teams (CMT) have been deployed – one in Tigray, one in Amhara, and one covering SNNP, Oromia and Somali regions. These teams provide on-site coaching to medical and laboratory staff involved in VL care, to ensure quality of case management of VL patients. Currently 19 facilities have received visits.
To date, WHO has conducted training in Somali and Amhara regions for more than 46 health professionals. Training and mentoring will support diagnostic practices and clinical case management of patients.
- Case management
Health Facility Assessments have been completed by KalaCORE in 17 health facilities where the vast majority of VL patients are diagnosed and treated (Amhara, Tigray, Oromia and SNNPR). Results showed that not all facilities were providing good quality care. Support for improving the standard of care in target facilities is ongoing in the following critical areas:
Strengthening laboratory and diagnostic capacity
Upgrading services for high numbers of VL patients during the peak season
Minor infrastructure work and provision of equipment to ensure quality care while MoH finishes upgrading health facilities.
We are working with the Ethiopian government and the World Health Organization (WHO) to ensure coordination between our plans and the broader health sector development plan to ensure service provision in new and/or improved facilities.
- Case management
KalaCORE procures the VL treatment drugs, Sodium stibogluconate (SSG) and Paromomycin, as well as rapid diagnostic tests and donates these to the Ethiopian Government. Supplies are transferred to the Ethiopian Government’s Pharmaceutical Fund and Supply Agency (PFSA) who distribute them via established channels. KalaCORE also provides technical assistance for forecasting drug needs and follows up in the field with the teams to ensure no stock ruptures.
Over 3 years, KalaCORE expects to provide diagnostics and drugs for diagnosing and treating around 7,000 VL patients.